Lentiviruses have been widely used for cell therapy based applications. This presentation will showcase IDT Biologika’s platform based approach for Lentiviral Vector production.

Additionally, analytical methods for determining both the physical and functional titer will be described, which are used to assess the efficiency of Lentiviral Vector production.

The strategies described here will enable a scalable and robust process that focuses on suspension transient transfection of serum free HEK cells.